We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Provence Technologies Acquires Synprosis

News   Jun 03, 2014

 
Provence Technologies Acquires Synprosis
 
 
Advertisement
 

RELATED ARTICLES

Recreating Nature: Chemists Create Synthetic Version of Natural Anti-Cancer Agent

News

Scripps Research chemists Hans Renata, PhD, and Alexander Adibekian, PhD, have discovered a way to efficiently create a synthetic version of a valuable natural compound called cepafungin I, which has shown promise as an anti-cancer agent.

READ MORE

NIH Announces Clinical Trial To Test Monoclonal Antibodies for COVID-19

News

A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.

READ MORE

Circulating DNA From Tumor Could Predict Immunotherapy Outcome

News

A newly developed test that detects changing levels of tumor fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, according to researchers.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE